LentiTherapy™ - Cell Specific & Non Toxic Transduction Technology

LentiTherapy™ is designed to enable cell type specific transduction and improve standard transduction efficiencies. The system is a great candidate for clinical research applications because of its universal applicability and non-toxic chemistry. Proven effective in CD30 and EGFR positive cell types.

The LentiTherapy™ 3 hit strategy to target therapeutically relevant cell types

Step 1: Retargeting antibody fragments on the virus envelope. These single-chain antibody fragments have a high affinity and specificity to peripheral proteins of cell surfaces, allowing targeted precision of viral transduction.

Step 2: LentiBOOST™ transduction enhancer increases the permeability of cell membranes, allowing lentiviruses easy access. The chemical basis for LentiBOOST™ is non-toxic and is used as a standard component in pharmaceutical pill formulation. This unique transduction enhancer is especially potent when used on non-adherent cells such as B-cell and T-cell transduction.

Step 3: Spinoculation increases the number of virusparticles binding to the cellsthrough centrifugal inoculation, enhancing the effectivenessof LentiBOOST™ and the retargeted envelope even further.

Due to its non-toxicity, the process is well suited for basic research as well as early clinical applications. LentiTherapy™ achieves sufficient genetic modification at low MOIs (less or equal to 1).

The figures show transduction experiments in KARPAS-299, SUP-M2 and SUDHL-1 cell lines incubated at MOI 10 or with copGFP-coding lentiviral particles +/- a spinoculation protocol, LentiBOOST (TM) and retargeted scFv-CD30 VSV-G lentivirus.

LentiTherapy™ is effective independent of cell type. The steps of this system influence each other synergistically, as demonstrated in the figure above. The treatment is effective at different MOIs and ideal for treating otherwise hard to transduce,therapeutically relevant cell types.

The LentiBOOST™transduction enhancer has been reported by collaborators from the academic sciences at the NYU Langone Medical Center to increase T-cell transduction significantly.

SIRION Biotech is searching for collaboration partners to help actively develop the application of the LentiTherapy™ Systemin pre-clinical and early clinical stages.


Höfig et al.,Systematic improvement oflentivirus transduction protocols by antibodyfragments fused to VSV-G as envelope glycoprotein. J. Biomaterials(2014)